TRGC1: A Liquid Chromatography Method for Separation and Detection of Biomolecules

Target Name: TRGC1

NCBI ID: G6966

TRGC1

Other Name(s): C1 | T cell receptor gamma constant 1 | TCRG | TCRGC1

TRGC1: A Liquid Chromatography Method for Separation and Detection of Biomolecules

TRGC1 (Tetrand vertical and horizontal liquid chromatography), also known as C1, is a separation and analytical technique widely used in drug discovery and biochemical research. It can be used to detect and separate complex biomolecule mixtures, such as proteins, nucleic acids, and polysaccharides.

TRGC1 works by mixing the mixture with a solution called a "traversal liquid phase" and then separating the mixture on a high-speed rotating chromatography column. The chromatographic column is composed of two different materials, one is a polymer material and the other is a low molecular material. The polymer material remains relatively stationary during the rotation, while the low molecular material moves rapidly along the inner wall of the column. Because different molecules have different properties such as molecular weight, size, and charge, they move at different speeds during rotation, thereby achieving separation.

TRGC1 technology has a wide range of applications in drug research and development, such as the detection and separation of proteins, such as insulin, growth factors and drugs. It can separate and detect complex mixtures of biomolecules, helping researchers better understand the properties and behavior of these molecules.

TRGC1 can also be used in other fields in biochemical research, such as nucleic acid analysis, polysaccharide analysis, etc. It can be used to detect and separate biomolecules such as nucleic acids and polysaccharides, helping researchers better understand the properties and behavior of these molecules.

TRGC1 is an important technology that can be used to detect and separate complex biomolecule mixtures. It can also play an important role in drug development and biochemical research, helping researchers better understand the properties and behavior of these molecules. With the continuous development of technology, the application prospects of TRGC1 will become more and more extensive in the future.

Protein Name: T Cell Receptor Gamma Constant 1

Functions: Constant region of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447). Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. Upon antigen recognition induces rapid, innate-like immune responses involved in pathogen clearance and tissue repair (PubMed:28920588, PubMed:23348415). Binding of gamma-delta TR complex to antigen triggers phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains by the LCK and FYN kinases, allowing the recruitment, phosphorylation, and activation of ZAP70 that facilitates phosphorylation of the scaffolding proteins LCP2 and LAT. This lead to the formation of a supramolecular signalosome that recruits the phospholipase PLCG1, resulting in calcium mobilization and ERK activation, ultimately leading to T cell expansion and differentiation into effector cells (PubMed:25674089). Gamma-delta TRs are produced through somatic rearrangement of a limited repertoire of variable (V), diversity (D), and joining (J) genes. The potential diversity of gamma-delta TRs is conferred by the unique ability to rearrange (D) genes in tandem and to utilize all three reading frames. The combinatorial diversity is considerably increased by the sequence exonuclease trimming and random nucleotide (N) region additions which occur during the V-(D)-J rearrangements (PubMed:24387714)

The "TRGC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRGC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets